

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Anderson, et al.
 Appln. No.: 08

921,060
 Serial No. ↑

Filed: August 29, 1997

Hon. Commissioner of Patents
 Washington, D.C. 20231

Sir:

Group Art Unit 1644

Examiner: R. Schwadron

Atty. Dkt. P 0275463

Client Ref

Appln. Title: THERAPEUTIC APPLICATION OF
 CHIMERIC AND RADIOLABELED
 ANTIBODIES TO HUMAN B
 LYMPHOCYTE RESTRICTED
 DIFFERENTIATION ANTIGEN FOR
 TREATMENT OF B CELL LYMPHOMA

Date: July 19, 2002



REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code
A. <input type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input type="checkbox"/> made previously						
For B & C See Required Separate Paper (Pat-256)						
2. Total Effective Claims	**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add				+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: May 11, 2002	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo)	\$110/\$55 =		+ \$920		115/215
	(2 mos)	\$400/\$200 =				116/216
	(3 mos)	\$920/\$460 =				117/217
	(4 mos)	\$1,440/\$720 =				118/218
	(5 mos)	\$1,960/\$980 =				128/228
7. Enter any previous extension fee paid since above original due date and subtract				- \$110		
8.				Extension Fee	+ \$810	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee				+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add				+ \$180	+ \$0	126
or if Rule 97(d) Request add				+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)				x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)				+ \$740/370	+ \$0	1179/1279
14. Petition fee for					+ \$0	
15.				TOTAL FEE =	\$810	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".						
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.						
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.						

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275463
 C# M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

07/23/2002 AMONDAF1 00000098 033975 08921060

01 FC:117

810.00 CH

1600 Tysons Boulevard
 McLean, VA 22102
 Tel: (703) 905-2000

Pillsbury Winthrop LLP
 Intellectual Property Group

By Atty: Robin L. Teskin

Sig:


Reg. No. 35,030

Fax: (703) 905-2500
 Tel: (703) 905-2200

Atty/Sec: RLT/DJM

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

RECEIVED
 JUL 24 2002



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application Serial No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

* * * * *

REPLY AND AMENDMENT
PURSUANT TO 37 C.F.R. §1.116

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [final rejection] dated February 11, 2002 and in further response to the Advisory Action dated July 9, 2002, please amend the above-identified application as follows.

IN THE CLAIMS

Please cancel claims 14 and 15 without prejudice.

Please enter the following amended claims:

11. (Twice Amended) A method of treating a human patient suffering from B-cell lymphoma comprising the following steps:

(i) administration of a non-radiolabeled chimeric anti-CD20 antibody which itself when administered at a dosage of 0.4 mg/kg body weight results in nearly complete peripheral B-cell depletion within about 24 hours post treatment infusion; and

(ii) administration of at least one chemotherapeutic agent.

16. (Amended) A method of treating a human patient suffering from B cell lymphoma comprising the following steps:

(i) administration of a non-radiolabeled chimeric anti-CD20 antibody which itself when administered at any dosage between 0.4 to 20.0 mg/kg body weight results in nearly complete peripheral B cell depletion within about 24 hours post treatment infusion; and

(ii) administration of at least one chemotherapeutic agent.